StockGuru Shines its Spotlight on Amarantus BioSciences, Inc. (OTCBB: AMBS) Amarantus BioSciences Presents Summary of Peer-Reviewed Data for Parkinson’s Program – August 3, 2011

StockGuru Shines its Spotlight on Amarantus BioSciences, Inc. (OTCBB: AMBS) Amarantus BioSciences Presents Summary of Peer-Reviewed Data for Parkinson’s Program – August 3, 2011

Scientific Literature Provides Compelling Rationale for Further Development

Dallas, Texas (August 3, 2011) – StockGuru shines its Spotlight on Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class, disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis, yesterday presented a summary of the peer-reviewed findings reported to date in prominent scientific journals that provide a compelling scientific rationale for the further development of the Company’s Parkinson’s program. The publications, appearing in seven different scientific journals, indicate that MANF’s molecular properties make it an attractive development candidate for the treatment of Parkinson’s disease. This announcement follows data reported last week, in which Amarantus reproduced key pre-clinical data that provides a sound scientific rationale to focus the MANF Parkinson’s development program on the protocols required to gain regulatory approval to initiate human clinical studies.  The Company closed on August 2, 2011 at $0.28, trading in a fifty two week range of $1.50 – 0.06.

“The scientific community is generally quite conservative when it comes to the evaluation of new drug candidates for the treatment of poorly-served conditions such as Parkinson’s disease,” said Martin D. Cleary, Chief Executive Officer of Amarantus. “The breadth of data published over the last 8 years in these leading scientific journals represents significant external scientific validation of MANF’s potential and gives the Company a solid foundation to further invest in its Parkinson’s program to confirm MANF’s ability to slow or reverse the progression of this devastating disease.”

MANF is a novel protein that was discovered from Amarantus’ PhenoGuard Protein Discovery Engine, which uses the Company’s proprietary cell lines to discover neurotrophic factors with activity against specific neurodegenerative diseases. Neurotrophic factors are proteins that protect neurons from various insults and are promising drug candidates for Parkinson’s and other neurodegenerative diseases. The data reported below identifies a unique mechanism of action for MANF among neurotrophic factors:

  • In research reported in 2010 in The Journal of Biological Chemistry [286:2675-2680] researchers concluded that MANF has a unique mechanism to rescue neurons dying by apoptosis;
  • In a review published in 2010 in Developmental Neurobiology, [70:360-371], researchers reviewed the breadth of published data and concluded that MANF is a potential therapeutic protein for the treatment of Parkinson’s disease;
  • In research reported in 2009 The Journal of Neuroscience, [29(30):9651-9659], MANF demonstrated neurorestorative properties in a rodent model of Parkinson’s, MANF was also readily distributed throughout the striatum and demonstrated significant therapeutic potential for the treatment of Parkinson’s disease;
  • In research reported in 2009 in Proceedings of the National Academy of Sciences, [106:2429-2434], researchers concluded that MANF is essential for the maintenance of dopamine positive neurites and dopamine levels in Drosophila. Further, the knockout of MANF in Drosophila leads to degeneration of axonal bundles in the nervous system;
  • In a review published in 2007 in Science, [411:pe60], researchers reported that MANF was part of a new class of neurotrophic factors that may present advantages versus previously studied neurotrophic factors for Parkinson’s disease;
  • In research reported in 2006 in NeuroReport, [17:293-297], researchers concluded that MANF increases the release of the neurotransmitter GABA from pre-synaptic nerve terminals in the substantia nigra, which in turn may dampen the excitotoxic action of excessive glutamate that has been associated with dopaminergic cell death;
  • In research reported in 2003 in Journal of Molecular Neuroscience [20: 173-188], researchers announced the discovery of MANF and reported that MANF protects the dopaminergic neurons that degenerate in Parkinson’s disease in vitro.

“Combined with the results reported last week, these scientific publications provide significant independent validation for Amarantus’ lead candidate MANF’s potential to address the apoptotic neuronal death associated with Parkinson’s disease,” said John W. Commissiong, Chief Scientific Officer of Amarantus and discover of MANF. “The results published to date indicate that there are potentially several other CNS-related medical conditions where MANF could play a vital role due to its novel mechanism of action for rescuing apoptotic neurons. We fully intend to develop additional strategies to maximize the value of the extensive intellectual property portfolio the Company owns covering MANF to treat nervous system disorders.”

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is engaged in the research and development of first-in-class disease-modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases. The Company’s most advanced product candidate, MANF, is a therapeutic protein indicated for the treatment of Parkinson’s disease and Myocardial Infarction. Currently incubating at the Parkinson’s Institute in Sunnyvale, CA, Amarantus BioSciences is the recipient of a research grant from The Michael J. Fox Foundation for Parkinson’s Research. See

Forward Looking Safe-Harbor Statement:

The information provided herein may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Exchange Act of 1934. These forward-looking statements are largely based on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Such forward-looking statements include, in particular, statements about our plans, strategies, business prospects, and the ongoing and future development of disease modifying treatments. These forward-looking statements may be identified by the use of terms and phrases such as “anticipates”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “plans”, “projects”, “targets”, “will”, and similar expressions or variations of these terms and similar phrases. Additionally, statements concerning future matters such as planned research and development and the regulatory approval, marketing, and sale of planned future and other statements regarding matters that are not historical are forward-looking statements. Management cautions that these forward-looking statements relate to future events or our future financial performance and are subject to business, economic, and other risks and uncertainties, both known and unknown, that may cause actual results, levels of activity, performance or achievements of our business or our industry to be materially different from those expressed or implied by any forward-looking statements.

These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, including without limitation, the following: (a) the risk that our product candidate MANF, which is still under clinical development, may not obtain regulatory approval or be successfully commercialized; (b) the risk that extensive regulatory requirements may limit the scope of future sales or impede successful product commercialization even if we obtain regulatory approval for our product candidate; (c) the risk that we may be unable to arrange for the successful manufacture and commercial supply of our planned product; (d) the risk that MANF, if approved and brought to market, may not be accepted by the medical community; (e) the risk that we may not be successful in undertaking the steps currently planned in order to increase our liquidity and capital resources, resulting in inadequate funding for our planned research and development activities; and (f) other risks and uncertainties described in our filings with the Securities and Exchange Commission.

Neither management nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. All forward-looking statements in this press release are made as of the date hereof, based on information available to us as of the date hereof, and subsequent facts or circumstances may contradict, obviate, undermine, or otherwise fail to support or substantiate such statements. We caution you not to rely on these statements without also considering the risks and uncertainties associated with these statements and our business that are addressed in our filings with the Securities and Exchange Commission that are available on the SEC’s web site located at Certain information included in this press release may supersede or supplement forward-looking statements in our other Exchange Act reports filed with the SEC. We assume no obligation to update any forward-looking statement to conform such statements to actual results or to changes in our expectations, except as required by applicable law or regulation.

To view this StockGuru Spotlight, please visit:

To get free alerts on this and other similar stocks, please register here:

What is the StockGuru Spotlight?

Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.

StockGuru looks for potential break-out candidates in The StockGuru Spotlight.  Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage.  There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below.   StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.

To feature a company in The StockGuru Spotlight please contact the Publisher at  If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact the StockGuru Publisher John Pentony at this email address: (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions.  SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage.  When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present.  Additionally SG also discloses any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

John Pentony, Publisher,

Tel: +1 469 252 3031